AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$BHC

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BHCNeutralMed
01

Why it matters

The earnings beat and raised guidance provide fresh data for valuation models and may influence analyst revisions.

02

Market read

First report of Bausch Health's Q3 results and FY2026 guidance, a material earnings event for a mid‑cap pharma stock.

03

What to watch

Potential headwinds from China tariffs and competitive pressure in skin‑tightening market.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Bausch Health reported Q3 performance across its international, Latin America, and Solta Medical segments, highlighted debt reduction and a $50M share repurchase.

Company-level read

Ticker impact

$BHCNeutralHigh confidence
Context

Bausch Health disclosed Q3 results and raised full-year guidance, including revenue $5.525‑$5.625B and adjusted EBITDA $3.225‑$3.275B.

Expected impact

potential upside as market prices in higher revenue and EBITDA guidance

Evidence & confidence

New guidance and cash‑flow outlook are primary disclosures not previously reported, providing fresh material for valuation.

Market effects

Sector

Improved outlook for specialty pharma may lift peers in the sector.

Regional

Positive guidance could boost North American pharma sentiment.

Global

Adds to broader market earnings momentum for the quarter.

Counterpoint

What could challenge this read

If guidance already priced in, the stock may face disappointment on execution risk.

Key entities

  • Executive
    Thomas Appio

    CEO who presented the earnings and outlook.

  • Executive
    Charhon

    Spokesperson discussing debt reduction and capital allocation.

Read at source← All news

StoryBausch Health posts strong Q3 2026 results, raises full‑year outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 28
$BHCHighAI 8/10

[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027

Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.

finance.biggo.com3 min
OCT 28
$BHCHighAI 8/10

Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion

Bausch Health reported a 32% YoY increase in adjusted EBITDA to $1.305 billion for Q3FY26, exceeding $1 billion for the first time. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, citing strong performance. Net debt was reduced by $521 million during the quarter. Salix segment drove growth with a 16% revenue increase, while Solta Medical saw reported revenue grow 18% but organic revenue decline 4%.

scanx.trade3 min